Director, Health Economics & Outcomes Research (HEOR) – ARGO Franchise

About the Role 

Azurity Pharmaceuticals is a privately held specialty pharmaceutical company focused on innovative products that meet the needs of underserved patients. Within the ARGO franchise — our hospital-focused, targeted-delivery specialty business — we are building the value-evidence foundation for a portfolio of hospital and institutional products, beginning with D-PLEX100, a locally administered, extended-release surgical anti-infective for the prevention of surgical site infection. 

We are seeking a Director, Health Economics & Outcomes Research (HEOR) to develop the HEOR evidence, economic models, and value dossiers that support access and reimbursement for ARGO's products in the US and Canada. Reporting to the VP, Commercial Brand Executive for ARGO, this individual owns the value-evidence strategy and deliverables for the franchise — starting with D-PLEX100 and extending to future assets — and translates clinical and economic data into the tools that hospital, payer, and health-technology-assessment decision-makers require. 

Because ARGO's products are inpatient and institutionally reimbursed, this role is central to the commercial model: the HEOR Director builds the budget-impact and cost-effectiveness evidence that underpins DRG economics, the New Technology Add-On Payment (NTAP) application, hospital coding strategy, and the P&T and value-analysis-committee value story. The role partners closely with Market Access, Medical Affairs, Brand Marketing, the field organization, Regulatory, and Program Management, and manages external HEOR vendors and academic collaborators. 

The ideal candidate brings a minimum of 8 years of HEOR, health economics, or value & access experience in pharmaceutical, biotech, or device, including dossier and economic-model development and US reimbursement strategy. Hospital / inpatient, anti-infective, surgical, or device experience and familiarity with both US and Canadian access environments are strongly preferred. 

Key Responsibilities 

Value Evidence Strategy 

• Own the HEOR and value-evidence strategy for the ARGO franchise, beginning with D-PLEX100, and build the integrated evidence plan that supports US and Canadian access and reimbursement across the product lifecycle. 
• Identify evidence gaps against the requirements of hospital decision-makers, payers, and health-technology-assessment (HTA) bodies, and prioritize the studies and analyses needed to close them. 
• Define the economic value proposition for an inpatient, DRG-reimbursed surgical product, and align it with brand strategy and market-access objectives. 

Dossiers, Models & Deliverables 

• Lead development of value dossiers — including the AMCP dossier — and the supporting clinical and economic evidence summaries for ARGO products. 
• Build and maintain budget-impact and cost-effectiveness models, cost-of-care and cost-offset analyses (e.g., the economic burden of surgical site infection), and account-level value calculators for institutional customers. 
• Develop payer, hospital, and P&T / value-analysis-committee value tools and objection-handling materials, and equip the field and account teams with compliant value narratives. 

Reimbursement, NTAP & Coding 

• Lead the health-economic and evidence components of the New Technology Add-On Payment (NTAP) application and other inpatient add-on payment pathways, in partnership with Market Access and Program Management. 
• Develop the hospital coding and reimbursement strategy — MS-DRG mapping, HCPCS/ICD coding, and the economic case for appropriate reimbursement — and produce supporting materials for hospital finance and revenue-cycle stakeholders. 
• Model DRG economics and the payment landscape so pricing, contracting, and the value story reflect how the product is actually reimbursed in the inpatient setting. 

Evidence Generation & Publication 

• Design and oversee HEOR studies — retrospective database, real-world evidence, chart review, and pragmatic analyses — using claims, EHR, and registry data, executed with internal teams and external vendors. 
• Collaborate with clinical, biostatistics, and evidence-generation colleagues on outcomes endpoints and real-world evidence, and with KOLs on study design and authorship. 
• Drive the HEOR publication and communication plan — abstracts, posters, and manuscripts for congresses such as ISPOR, AMCP, and IDWeek — to make the evidence available to decision-makers. 

US & Canada Access Support 

• Support US field engagement with payers, hospital systems, IDNs, and population-health decision-makers, providing compliant health-economic evidence and training. 
• Develop the Canadian value-evidence and HTA strategy — CDA-AMC (formerly CADTH) and INESSS submissions, pan-Canadian considerations, and hospital / provincial access requirements — as D-PLEX100 advances in Canada. 
• Monitor evolving evidence requirements, HTA methods, and ICER-type assessments, and prepare responses relevant to ARGO products. 

Measures of Success 

• Evidence readiness: the AMCP dossier, budget-impact model, and core value tools are complete, reviewed, and available ahead of launch. 
• Reimbursement support: the HEOR components of the NTAP application and hospital coding strategy are delivered on schedule and support the reimbursement objective. 
• Field enablement: payer, hospital, and P&T value tools are adopted and used by the field and account teams. 
• Evidence generation: prioritized HEOR studies and publications are executed to plan, closing the evidence gaps that matter to decision-makers. 
• Canada: the Canadian HEOR and HTA plan is defined and progressing to the market timeline. 

Required Skills and Experience 

• Advanced degree in health economics, outcomes research, pharmacy, epidemiology, public health, or a related field (PhD, PharmD, or Master's); Bachelor's with commensurate experience considered. 
• 8+ years of HEOR, health economics, or value & access experience in pharmaceutical, biotech, or medical device. 
• Demonstrated ownership of value dossiers (including AMCP dossier) and economic models (budget-impact and cost-effectiveness). 
• Working knowledge of US reimbursement — including inpatient DRG economics, add-on payment (NTAP), and hospital coding (MS-DRG, HCPCS/ICD) — sufficient to build the economic case for a hospital-administered product. 
• Experience designing and overseeing HEOR studies using real-world data (claims, EHR, registries), including work with external vendors and academic collaborators. 
• Strong communication skills, including the ability to translate economic analysis into decision-ready value narratives for payer, hospital, and P&T audiences. 
• Proven cross-functional collaboration with Market Access, Medical Affairs, Commercial, and Clinical/Regulatory. 
• Willingness to travel ~20–30% (including congresses, advisory boards, and customer or vendor meetings). 

Preferred Qualifications 

• Hospital / inpatient, anti-infective, surgical, or drug-device product HEOR experience strongly preferred. 
• Direct experience supporting an NTAP application or other inpatient add-on payment pathway. 
• Familiarity with hospital P&T and value-analysis-committee decision-making and with antimicrobial-stewardship / infection-prevention economics. 
• Canadian HTA experience (CDA-AMC / CADTH, INESSS) and knowledge of provincial and hospital access. 
• HEOR experience with an in-licensed or newly acquired asset. 
• Publication record in HEOR or health-economics venues (e.g., ISPOR, AMCP). 

#LI-Remote
#LI-Full-time